- ByInvesting.com-
On Tuesday, AutoZone, Inc. (NYSE:AZO) received a positive outlook from Mizuho Securities as the firm initiated coverage on the automotive parts retailer with a Buy rating and a...
Last | Chg. | ||||
---|---|---|---|---|---|
1.82 | +0.64 | +54.24% | 9.18M | ||
0.326 | +0.1360 | +71.58% | 5.66M | ||
0.3702 | +0.0102 | +2.83% | 4.27M | ||
1.36 | +0.28 | +25.93% | 2.92M | ||
0.61 | +0.03 | +5.78% | 1.49M | ||
8.09 | -0.15 | -1.82% | 1.4M | ||
1.55 | +0.450 | +40.91% | 1.31M | ||
0.029 | 0.000 | -0.34% | 1.31M | ||
0.147 | +0.0002 | +0.14% | 1.1M | ||
172.04 | -1.76 | -1.01% | 885.72K |
Name | Last | Chg. % | Vol. |
---|---|---|---|
5.05 | +390.29% | 0.02K | |
21.26 | +99.81% | 721.82K | |
0.326 | +71.58% | 5.66M | |
1.82 | +54.24% | 9.18M | |
18.00 | +53.58% | 0.02K | |
1.55 | +40.91% | 1.31M | |
3.93 | +36.46% | 0.02K | |
1.36 | +25.93% | 2.92M | |
1.20 | +24.35% | 124.97K | |
5.22 | +23.70% | 45.77K |
Name | Last | Chg. % | Vol. |
---|---|---|---|
0.1639 | -56.06% | 492.64K | |
0.31 | -35.00% | 0.21K | |
4.56 | -32.94% | 301.91K | |
0.62 | -20.49% | 0.55K | |
0.606 | -18.37% | 5.72K | |
0.21 | -18.23% | 327.8K | |
0.60 | -16.21% | 0.2K | |
0.60 | -15.49% | 1.72K | |
15.60 | -14.19% | 72.62K | |
1.49 | -13.37% | 5.93K |
Time | Cur. | Imp. | Event | Actual | Forecast | Previous |
---|---|---|---|---|---|---|
Tuesday, 19 March 2024 | ||||||
12:30 | USD | 1.50M | 1.489M | |||
12:30 | USD | -0.30% | ||||
12:30 | USD | -14.80% | ||||
12:30 | USD | 1.43M | 1.331M | |||
12:55 | USD | 3.00% | ||||
15:30 | USD | 4.695% | ||||
16:30 | USD | 2.30% | 2.30% |
On Tuesday, AutoZone, Inc. (NYSE:AZO) received a positive outlook from Mizuho Securities as the firm initiated coverage on the automotive parts retailer with a Buy rating and a...
Tuesday, Mizuho initiated coverage on Advance Auto Parts (NYSE: NYSE:AAP) with a Neutral rating and a price target of $78. The firm highlighted the challenges the company...
On Tuesday, H.C. Wainwright initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company specializing in treatments for central nervous system (CNS)...
Augmedix, a provider of ambient class solutions for healthcare, has reported a significant revenue increase for the fourth quarter of 2023, with a 45% year-over-year growth...
Lantern Pharma, a leader in AI-driven drug discovery and development, reported its financial results for the fourth quarter and full year of 2023 during its earnings call. The...
With the last half of March upon us, the blackout of stock buybacks threatens to reduce one of the liquidity sources supporting the bullish run this year. If you don’t understand...
The Russell 2000 (IWM) has been defending its 50-day MA over the early part of 2024, but the last few days have seen a shift in this support with 'sell' triggers in the MACD and...
If you had been following the S&P 500 closely this past week, it likely would have left you scratching your head if you were trying to align the news with the market action. For...
Amid upcoming central bank meetings and crucial macroeconomic data releases, market sentiment is poised for potential shifts. While broader market indexes may continue to...
Last week we wrote about how M&A activity has been light so far for 2024, well the same holds for IPO activity. However, next week brings two highly anticipated public debuts that...